Illumina, Inc. (ILMN)
| Previous Close | 163.94 |
| Open | 163.97 |
| Bid | 160.15 x 800 |
| Ask | 160.32 x 2900 |
| Day's Range | 159.50 - 164.00 |
| 52 Week Range | 159.50 - 248.87 |
| Volume | |
| Avg. Volume | 1,588,545 |
| Market Cap | 25.955B |
| Beta (5Y Monthly) | 1.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -26.77 |
| Earnings Date | Nov 01, 2023 - Nov 06, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 213.56 |
Motley FoolWall Street Thinks Illumina Stock Will Rise 27% in 1 Year. Here's Why That Probably Won't Happen.
Wall Street analysts are upbeat on California-based biotech Illumina (NASDAQ: ILMN) these days, estimating on average that the stock could climb by up to 27% over the next year. The most important reason why Illumina's shares are unlikely to rise that much in the near term is that nobody is anticipating an uptick in sales of the gene sequencers that Illumina makes -- or the consumable reagents that those sequencers need in perpetuity if they're to be usable by customers. To make matters worse, its sales of consumables, which totaled $739 million in the second quarter, actually dropped by 1% year over year.
ZacksIllumina (ILMN) Expands Presence in India With New Facility
Illumina (ILMN) boosts genomic capabilities in India with a new state-of-the-art Solutions Center.
ZacksEXEL or ILMN: Which Is the Better Value Stock Right Now?
EXEL vs. ILMN: Which Stock Is the Better Value Option?
